Listen and subscribe to Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you find your favorite podcasts. After completing $300 billion in healthcare deals over several decades, there ...

As a fully integrated eye health business, Bausch + Lomb has an established line of contact lenses, intraocular lenses (“IOLs”) and other medical devices, surgical systems and devices ...

For the full year, Bausch and Lomb sees sales in a range of $4.95 billion to $5.05 billion. The Street was at $5.02 billion. The company forecast its dry-eye business to break $1 billion in sales ...

2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and ...

Bausch Health Companies owns 88.4% of Bausch and Lomb. Saunders believes interested buyers undervalued the company's product pipeline, which includes new technologies for contact lenses, dry eye ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a prominent player in the global eye health market with a market capitalization of $5.78 billion, has been navigating a complex landscape of ...